Trial intelligence / Profile preview

Nivolumab and ASTX727 in Relapsed or Refractory B-cell Lymphoma

NCT05272384Phase 1Recruiting

Sponsor: National Cancer Institute
Start: Nov 2022
Primary completion: Jun 2027
Modality: Small Molecules, Monoclonal Antibodies
Countries: 1

Overview

Phase 1, open-label, single-arm trial of nivolumab, decitabine and cedazuridine in B cell lymphoma, diffuse large B-cell lymphoma (DLBCL) and Hodgkin lymphoma (HL), sponsored by National Cancer Institute. Primary endpoint: Incidence of adverse events up to 2 years. Started Nov 2022; status: recruiting.

Drugs

nivolumabdecitabinecedazuridine

Conditions

B cell lymphomadiffuse large B-cell lymphoma (DLBCL)Hodgkin lymphoma (HL)

Beyond the preview

Go deeper on NCT05272384.

Study design, results and competitive context are available in the Gosset platform where reported.

Study design & results

Available in the Gosset platform where reported.

Competitive context

Available in the Gosset platform where reported.

Bring the full picture into focus.

See how Gosset can support your research on NCT05272384.